Evidence map›Paper›PMID 42429921›Full record

Trial reportEuropean journal of drug metabolism and pharmacokinetics2026

Randomized Study About Influence of Food on the Pharmacokinetics of Disulfiram Metabolites in Healthy Individuals.

Gabriel P E Silveira, Douglas P Pinto, Luciana F Portela, Sheila Suarez Fontes, Juliana Almeida-Silva, Alessandra L Viçosa, Sandra Aurora C Perez, Marcos André Vannier-Santos, Rita Estrela, Roberto M Saraiva

Abstract readRandomized Controlled TrialClinical Trial, Phase I
PubMed Publisher
In one paragraph

Trial report in European journal of drug metabolism and pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gabriel P E SilveiraEquivalence and Pharmacokinetics Service (Sefar), Oswaldo Cruz Foundation, Av Brasil 4365, Rio de Janeiro, RJ, Brazil.ORCID http://orcid.org/0009-0007-5082-7312
Douglas P PintoEquivalence and Pharmacokinetics Service (Sefar), Oswaldo Cruz Foundation, Av Brasil 4365, Rio de Janeiro, RJ, Brazil.ORCID http://orcid.org/0000-0001-9278-4890
Luciana F PortelaEvandro Chagas Infectious Disease National Institute, Oswaldo Cruz Foundation, Av Brasil 4365, Rio de Janeiro, RJ, 21040-900, Brazil.ORCID http://orcid.org/0000-0001-8961-468X
Sheila Suarez FontesInnovations in Therapies, Education and Bioproducts Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Av Brasil 4365, Rio de Janeiro, RJ, Brazil.ORCID http://orcid.org/0000-0003-4925-0660
Juliana Almeida-SilvaInnovations in Therapies, Education and Bioproducts Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Av Brasil 4365, Rio de Janeiro, RJ, Brazil.ORCID http://orcid.org/0000-0002-3922-3514
Alessandra L ViçosaExperimental Pharmacotechnics Laboratory, Department of Galenic Innovation, Institute of Drug Technology - Farmanguinhos, Oswaldo Cruz Foundation, Av Brasil 4365, Rio de Janeiro, RJ, Brazil.ORCID http://orcid.org/0000-0001-8511-0003
Sandra Aurora C PerezProject Management Technical Assistance, Institute of Drug Technology - Farmanguinhos, Oswaldo Cruz Foundation, Av Brasil 4365, Rio de Janeiro, RJ, Brazil.ORCID http://orcid.org/0009-0002-0252-7394
Marcos André Vannier-SantosInnovations in Therapies, Education and Bioproducts Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Av Brasil 4365, Rio de Janeiro, RJ, Brazil.ORCID http://orcid.org/0000-0001-9241-2261
Rita EstrelaSérgio Arouca National School of Public Health, Oswaldo Cruz Foundation, Av Brasil 4365, Rio de Janeiro, RJ, Brazil.ORCID http://orcid.org/0000-0002-5653-1690
Roberto M SaraivaEvandro Chagas Infectious Disease National Institute, Oswaldo Cruz Foundation, Av Brasil 4365, Rio de Janeiro, RJ, 21040-900, Brazil. roberto.saraiva@ini.fiocruz.br.ORCID http://orcid.org/0000-0002-2263-4261

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 443886/2018-0Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro 211.167/2019Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/210.102/2023Fundação Oswaldo Cruz 6221125199
6 · The paper itself

Abstract

BACKGROUND AND

objectiveDisulfiram (DSF) is a substance registered as an adjunct in the treatment of alcoholism, and its repurposing for several different diseases is under investigation. Our study aimed to investigate the pharmacokinetic behavior of DSF plasmatic metabolites (methyl diethyldithiocarbamate (Me-DDC) and S-methyl N,N-diethylthiocarbamate (Me-DTC) under fasting and fed conditions.

methodsThis is an exploratory phase 1, open label, randomized and crossover study where healthy participants took 250 mg or 500 mg of DSF tablets with or without a high-fat meal. Me-DDC and Me-DTC were extracted from blood plasma and quantified by mass spectrometry. Pharmacokinetic parameters were determined by non-compartmental analysis.

resultsMe-DDC and Me-DTC peak plasma concentrations (C

conclusionAdministration of a high-fat meal before a single oral dose of DSF promoted a significant increase in the pharmacokinetic parameters C

Indexed as

Alcohol DeterrentsDisulfiramDitiocarbFood-Drug InteractionsAdultArea Under CurveCross-Over StudiesDose-Response Relationship, DrugFastingFemaleHealthy VolunteersHumansMaleYoung AdultAlcohol DeterrentsDisulfiramDitiocarb

Identifiers

PMID42429921

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.